MTM(SH:688029) Sou Hu Cai Jing·2025-07-30 09:29Company Performance - As of July 30, 2025, Nanwei Medical (688029) closed at 84.9 yuan, with an increase of 0.98% and a turnover rate of 2.66% [1] - The latest quarterly report shows total revenue of 699 million yuan, a year-on-year increase of 12.75%, and a net profit attributable to shareholders of 161 million yuan, up 12.18% year-on-year [1] - The company's non-recurring net profit is also 161 million yuan, reflecting a year-on-year growth of 14.20% [1] - Key financial ratios include a current ratio of 4.559, a quick ratio of 3.688, and a debt-to-asset ratio of 15.98% [1] Capital Flow - On the reporting day, the net inflow of main funds was 13.715 million yuan, accounting for 3.24% of the total transaction amount [1] - Large orders saw a net inflow of 23.0023 million yuan, representing 5.43% of the transaction amount, while large orders experienced a net outflow of 9.2873 million yuan, accounting for 2.19% [1] - Small orders had a net outflow of 28.1105 million yuan, which is 6.63% of the transaction amount [1] Company Background - Nanwei Medical Technology Co., Ltd. was established in 2000 and is located in Nanjing, focusing on research and experimental development [2] - The company has a registered capital of 1.878 billion yuan and a paid-in capital of 895.113 million yuan [1] - The legal representative of the company is Long Xiaohui [1] Investment and Intellectual Property - Nanwei Medical has made investments in 10 enterprises and participated in 1,610 bidding projects [2] - The company holds 73 trademark registrations and 543 patent registrations, along with 474 administrative licenses [2]